ViiV’s fostemsavir yields positive week 96 results in phase 3 HIV-1 trial
The company said that the week 96 data from the two-cohort BRIGHTE trial revealed that fostemsavir continued to improve virologic suppression and immunologic response. Fostemsavir is a prodrug